Search for biomarkers of Alzheimer's disease: Recent insights, current challenges and future prospects
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F19%3A43918845" target="_blank" >RIV/60461373:22340/19:43918845 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10400049 RIV/00064165:_____/19:10400049
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0009912018311858?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0009912018311858?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.clinbiochem.2019.04.002" target="_blank" >10.1016/j.clinbiochem.2019.04.002</a>
Alternative languages
Result language
angličtina
Original language name
Search for biomarkers of Alzheimer's disease: Recent insights, current challenges and future prospects
Original language description
Due to the trend of prolonged lifespan leading to higher incidence of age-related diseases, the demand for reliable biomarkers of dementia rises. In this review, we present novel biomarkers of high potential, especially those found in blood, urine or saliva, which could lead to a more comfortable patient experience and better time- and cost-effectivity, compared to the currently used diagnostic methods. We focus on biomarkers that might allow for the detection of Alzheimer's disease before its clinical manifestations. Such biomarkers might be helpful for better understanding the etiology of the disease and identifying its risk factors. Moreover, it could be a base for developing new treatment or at least help to prolong the presymptomatic stage in patients suffering from Alzheimer's disease. As potential candidates, we present, for instance, neurofilament light in both cerebrospinal fluid and blood plasma or amyloid beta in plasma. Above all, we provide an overview of different approaches to the diagnostics, analyzing patient's biofluids as a whole using molecular spectroscopy. Infrared and Raman spectroscopy and especially chiroptical methods provide information not only on the chemical composition, but also on molecular structure. Therefore, these techniques are promising for the diagnostics of Alzheimer's disease, as the accumulation of amyloid beta in abnormal conformation is one of the hallmarks of this disease.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10406 - Analytical chemistry
Result continuities
Project
<a href="/en/project/GA17-05292S" target="_blank" >GA17-05292S: Novel blood-based biomarkers for early diagnosis, prognosis and progress of Alzheimer's disease</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Biochemistry
ISSN
0009-9120
e-ISSN
—
Volume of the periodical
72
Issue of the periodical within the volume
OCT 2019
Country of publishing house
GB - UNITED KINGDOM
Number of pages
13
Pages from-to
39-51
UT code for WoS article
000486413800007
EID of the result in the Scopus database
2-s2.0-85064078438